Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. (September 2015)

• Record Type: Journal Article
• Authors: Kopylov, Uri; Yablecovitch, Doron; Lahat, Adi; Neuman, Sandra; Levhar, Nina; Greener, Tomer; Klang, Eyal; Rozendorn, Noa; Amitai, Marianne M; Ben‐Horin, Shomron; Eliakim, Rami
• Is Part Of: American journal of gastroenterology. Volume 110:Number 9(2015)
• Publication Date: 2015-09
• Subjects: Stomach -- Diseases -- Periodicals; Intestines -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Gastrointestinal Diseases -- Periodicals; Electronic journals; Periodicals; 616.33
• DOI: 10.1038/ajg.2015.221
• Languages: English
• ISSNs: 0002-9270

Abstract

Abstract : Objectives: Mucosal healing (MH) and deep remission (DR) are associated with improved outcomes in Crohn's disease (CD). However, most of the current data pertain to colonic MH and DR, whereas the evidence regarding the prevalence and impact of small bowel (SB) MH is scarce. The aim of this study was to to evaluate the prevalence of SBMH and DR in quiescent SBCD. Methods: Patients with known SBCD in clinical remission (CDAI<150) or with mild symptoms (CDAI<220) were prospectively recruited and underwent video capsule endoscopy after verification of SB patency. Inflammation was quantified using the Lewis score (LS). SBMH was defined as LS<135, whereas a significant inflammation was defined as LS>790. Clinico‐biomarker remission was defined as a combination of clinical remission and normal biomarkers. DR was defined as a combination of clinico‐biomarker remission and MH. Results: Fifty‐six patients with proven SB patency were enrolled; 52 (92.9%) patients were in clinical remission and 21 (40.4%) in clinico‐biomarker remission. SBMH was demonstrated in 8/52 (15.4%) of patients in clinical remission. Moderate‐to‐severe SB inflammation was demonstrated in 11/52 (21.1%) of patients in clinical remission and in 1/21 (4.7%) of patients in clinical and biomarker remission. Only 7/52 (13.5%) patients were in DR. Conclusions: SB inflammation is detected in the majority of CD patients in clinical and biomarker remission. SBMH and DR were rare and were independent of treatment modality. Our findings represent the true inflammatory burden in quiescent patients with SBCD.